ClinicalTrials.gg
CompletedNCT00477269Updated Mar 23, 2015Results posted

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

A Phase 2/3 interventional study of Imatinib mesylate and Placebo in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Enrollment
4th of 12
59 · median 27
Started
2006
the only one that year
Phase 2/3
Only one
of the 12
Registered
1st of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 4th largest by enrollment, is the only one that started in 2006, is the only one in phase 2/3, and was the 1st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Arterial Hypertension, tyrosine kinase inhibitor, STI571
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PAH of either primary (idiopathic), familial or secondary to systemic sclerosis (excluding those with marked pulmonary fibrosis) according to World Conference on Pulmonary Hypertension classification (Venice, 2003).
  • Symptoms with a WHO class of II-IV

Exclusion criteria

Exclusion Criteria:

  • Use of unspecific phosphodiesterase inhibitors (for example, pentoxyfillin, enoximon, milrinone or pimobendan) during the study
  • Chronic inhaled nitric oxide therapy from start to study completion
  • Treatment with catecholamines (for example, adrenalin, noradrenalin, dopamine),
  • Pre-existing lung diseases, including parasitic diseases affecting lungs, asthma, congenital abnormalities of the lungs, chest, and diaphragm.
  • Pulmonary artery or valve stenosis; pulmonary venous hypertension; chronic thromboembolic pulmonary hypertension
  • Acute heart failure or chronic left sided heart failure; congenital or acquired valvular or myocardial disease
  • Severe (systemic) arterial hypertension (> 200 mmHg (systolic) or > 120 mmHg (diastolic)) Other protocol-defined inclusion/exclusion criteria may apply
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    STI571

    STI571

    Drug: Imatinib mesylate

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    All Patients

    Open label extension

    Drug: Imatinib mesylate

Interventions

  • Also known as: Imatinib, Glivec, Gleevec, STI571, QTI571

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core

    In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.

    Time frame: 6 months

  2. Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Extension

    In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.

    Time frame: 72 months

  3. Change From Baseline of Six Minute Walk Test - Total Distance Walked at Different Time Periods

    The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

  4. Change From Baseline of Six Minute Walk Test - Number of Stops at Different Time Periods

    The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Number of stops were recorded for each patient.

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

  5. Change From Baseline of Six Minute Walk Test - Total Duration of Stops at Different Time Periods

    The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. If the patient stopped the duration of each stop was recorded.

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

Secondary outcomes

  1. Number of Patients With Pulmonary Hypertension (PAH) Assessd by World Health Organization (WHO) Classification on Physical Activity

    PAH assessed according to the WHO classification: Class I Patients with PAH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II Patients with PAH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III Patients with PAH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV Patients with PAH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion

  2. Borg Score-Oxygen Saturation(SaO2) During the Six Minutes Walk Test at Different Time Periods

    Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. The test was terminated if the patient became too distressed or if their SaO2% fell below 60%.

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

  3. Borg Score-Systolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods

    Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Systolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

  4. Borg Score-Diastolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods

    Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Diastolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

  5. Borg Score-Heart Rate (HR) During the Six Minutes Walk Test at Different Time Periods

    Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Heart Rate (bpm) were recorded before the test at resting, at the end of the test and two minutes after the end of the test

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

  6. Borg Score During the Six Minutes Walk Test at Different Time Periods

    Borg Score during Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Borg Score of Breathlessness was recorded using the following score of 0 to 10, how breathless do you feel? 0 is nothing at all and 10 is maximal breathlessness

    Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

  7. Mean Pulmonary Artery Pressure (PAP) at Baseline and Study Completion

    The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including right Pulmonary Arterial Pressure (PAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

    Time frame: Baseline, and Study completion (Week 24)

  8. Mean Pulmonary Artery Wedge Pressure (PAWP) at Baseline and Study Completion

    The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Arterial Wedge Pressure (PAWP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

    Time frame: Baseline, and Study completion (Week 24)

  9. Mean Systolic Arterial Pressure (SAP) at Baseline and Study Completion

    The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systolic Arterial Pressure (SAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

    Time frame: Baseline, and Study completion (Week 24)

  10. Mean Heart Rate (HR) at Baseline and Study Completion

    The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Heart Rate (HR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

    Time frame: Baseline, and Study completion (Week 24)

  11. Mean Cardiac Output (CO) at Baseline and Study Completion

    The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Cardiac Output (CO). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

    Time frame: Baseline, and Study completion (Week 24)

  12. Mean Pulmonary Vascular Resistance (PVR) at Baseline and Study Completion

    The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. PVR calculated according to the equation:PVR = (PAP - PCWP)/CO

    Time frame: Baseline, and Study completion (Week 24)

  13. Mean Systemic Vascular Resistance (SVR) at Baseline and Study Completion

    The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systemic Vascular Resistance (SVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. SVR was calculated according to the equation: SVR = (Paorta - Pright atrium)/CO

    Time frame: Baseline, and Study completion (Week 24)

  14. Blood Gas Measurement - PaO2 at Baseline and Study Completion

    The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaO2 levels at baseline and Study completion Week 24.

    Time frame: Baseline, and Study completion (Week 24)

  15. Blood Gas Measurement - PaCO2 at Baseline and Study Completion

    The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaCO2 levels at baseline and Study completion Week 24.

    Time frame: Baseline, and Study completion (Week 24)

  16. Blood Gas Measurement - PvO2 at Baseline and Study Completion

    The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PvO2 levels at baseline and Study completion Week 24.

    Time frame: Baseline, and Study completion (Week 24)

  17. Blood Gas Measurement - Arterial Saturation at Baseline and Study Completion

    The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Arterial Saturation levels at baseline and Study completion Week 24.

    Time frame: Baseline, and Study completion (Week 24)

  18. Blood Gas Measurement - Venous Saturation at Baseline and Study Completion

    The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Venous Saturation levels at baseline and Study completion Week 24.

    Time frame: Baseline, and Study completion (Week 24)

  19. Blood Gas Measurement - pH at Baseline and Study Completion

    The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including pH levels at baseline and Study completion Week 24. The pH scale measures how acidic or basic a substance is. It ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic.

    Time frame: Baseline, and Study completion (Week 24)

07

Results

Posted Mar 23, 2015

Participant flow

Of the 42 participants that completed the Core Study only 22 Participants continued into the Open Label Extension. Not all participants were required to continue into the extension from the core.

Core Study
Participant flow — Core Study
MilestoneSTI571PlaceboAll Patients
Started28310
Completed19230
Not completed980
Withdrew: Adverse event640
Withdrew: Death330
Withdrew: Withdrawn consent010
Open Label Extension
Participant flow — Open Label Extension
MilestoneSTI571PlaceboAll Patients
Started0022
Completed009
Not completed0013
Withdrew: Adverse event004
Withdrew: Abnormal laboratory values001
Withdrew: Unsatisfactory therapeutic effects002
Withdrew: Adminiatrative problems002
Withdrew: Death004

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core

In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.

Time frame:
6 months
Reported as:
Number · participants
Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core
participantsSTI571Placebo
Paients with AE(s)2729
Death33
SAE(s)1211
PrimaryNumber of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Extension

In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.

Time frame:
72 months
Reported as:
Number · participants
Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Extension
participantsAll Patients
Any AE(s)22
Death4
SAE(s)16
PrimaryChange From Baseline of Six Minute Walk Test - Total Distance Walked at Different Time Periods

The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Reported as:
Mean · meters
Change From Baseline of Six Minute Walk Test - Total Distance Walked at Different Time Periods
metersSTI571Placebo
Day 32 (n=25,27)10.2 ± 53.78.2 ± 27.5
week 8 (n=23,24)17.0 ± 55.615.5 ± 40.8
week 12 (n=22,24)21 ± 36.27.8 ± 50.0
week 16 (n=19, 23)25.5 ± 43.112.1 ± 47.9
week 20 (n=19, 21)38.3 ± 42.512.8 ± 60.4
study completion Week 24 (n=21, 12)22.0 ± 63.1-1.0 ± 53.3
PrimaryChange From Baseline of Six Minute Walk Test - Number of Stops at Different Time Periods

The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Number of stops were recorded for each patient.

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Reported as:
Mean · number of stops
Change From Baseline of Six Minute Walk Test - Number of Stops at Different Time Periods
number of stopsSTI571Placebo
Day 32 (n=25,27)-0.2 ± 0.70.1 ± 0.4
week 8 (n=23,24)-0.2 ± 0.70.0 ± 1.1
week 12 (n=22,24)-0.3 ± 0.90.3 ± 0.9
week 16 (n=19, 23)-0.3 ± 0.80.0 ± 0.2
week 20 (n=19, 21)-0.4 ± 1.00.3 ± 1.0
study completion Week 24 (n=21, 12)-0.3 ± 0.8-0.1 ± 0.5
PrimaryChange From Baseline of Six Minute Walk Test - Total Duration of Stops at Different Time Periods

The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. If the patient stopped the duration of each stop was recorded.

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Reported as:
Mean · minutes
Change From Baseline of Six Minute Walk Test - Total Duration of Stops at Different Time Periods
minutesSTI571Placebo
Day 32 (n=25,27)-0.06 ± 0.190.12 ± 0.36
week 8 (n=23,24)-0.03 ± 0.100.07 ± 0.27
week 12 (n=22,24)-0.03 ± 0.100.19 ± 0.55
week 16 (n=19, 23)-0.03 ± 0.100.06 ± 0.26
week 20 (n=19, 21)-0.05 ± 0.150.12 ± 0.42
study completion Week 24 (n=21, 12)-0.02 ± 0.100.03 ± 0.18
SecondaryNumber of Patients With Pulmonary Hypertension (PAH) Assessd by World Health Organization (WHO) Classification on Physical Activity

PAH assessed according to the WHO classification: Class I Patients with PAH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II Patients with PAH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III Patients with PAH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV Patients with PAH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion
Reported as:
Number · number of participants
Number of Patients With Pulmonary Hypertension (PAH) Assessd by World Health Organization (WHO) Classification on Physical Activity
number of participantsSTI571Placebo
Baseline: WHO Class IV (n=27,30)21
Baseline: WHO Class III (n=27,30)1422
Baseline: WHO Class II (n=27,30)117
Day 32: WHO Class IV (n=27,30)33
Day 32: WHO Class III (n=27,30)1121
Day 32: WHO Class II (n=27,30)136
Week 8: WHO Class IV (n=24,27)31
Week 8: WHO Class III (n=24,27)920
Week 8: WHO Class II (n=24,27)126
Week 12: WHO Class IV (n=23,27)01
Week 12: WHO Class III (n=23,27)1217
Week 12: WHO Class II (n=23,27)119
Week 16: WHO Class IV (n=22,27)01
Week 16: WHO Class III (n=22,27)1118
Week 16: WHO Class II (n=22,27)117
Week 16: WHO Class I (n=22,27)01
Week 20: WHO Class IV (n=19,24)01
Week 20: WHO Class III (n=19,24)1014
Week 20: WHO Class II (n=19,24)89
Week 20: WHO Class I (n=19,24)10
Week 24: WHO Class IV (n=21,25)12
Week 24: WHO Class III (n=21,25)1213
Week 24: WHO Class II (n=21,25)810
SecondaryBorg Score-Oxygen Saturation(SaO2) During the Six Minutes Walk Test at Different Time Periods

Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. The test was terminated if the patient became too distressed or if their SaO2% fell below 60%.

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Reported as:
Mean · Percentage of Oxygen Saturation
Borg Score-Oxygen Saturation(SaO2) During the Six Minutes Walk Test at Different Time Periods
Percentage of Oxygen SaturationSTI571Placebo
Baseline: Resting (n= 28, 29)94.3 ± 4.693.4 ± 4.7
Baseline: End of Test (n= 28, 28)87.9 ± 12.487.9 ± 8.2
Baseline: 2 minutes after end of test (n=26, 26)93.0 ± 7.092.0 ± 6.2
Day 32: Resting (n= 25, 28)94.5 ± 4.092.4 ± 6.3
Day 32: End of Test (n= 25, 28)89.0 ± 11.287.2 ± 12.8
Day 32: 2 minutes after end of test (n= 25, 26)94.8 ± 4.692.7 ± 7.1
Week 8: Resting (n= 23, 25)95.1 ± 3.393.2 ± 6.1
Week 8: End of Test (n= 23, 24)90.9 ± 6.787.9 ± 11.9
Week 8: 2 minutes after end of test (n= 23, 23)94.4 ± 5.393.1 ± 7.8
Week 12: Resting (n= 22, 25)95.1 ± 4.893.9 ± 5.6
Week 12: End of Test (n= 20, 24)89.8 ± 9.289.6 ± 8.9
Week 12: 2 minutes after end of test (n= 19, 22)92.7 ± 8.994.2 ± 5.6
Week 16: Resting (n= 19, 24)95.0 ± 5.094.1 ± 5.1
Week 16: End of Test (n= 18, 23)87.9 ± 13.188.1 ± 9.8
Week 16: 2 minutes after end of test (n= 19, 19)94.6 ± 6.093.3 ± 8.0
Week 20: Resting (n= 19, 22)94.0 ± 4.793.7 ± 5.0
Week 20: End of Test (n= 18, 21)87.5 ± 13.287.6 ± 9.1
Week 20: 2 minutes after end of test (n= 19, 21)93.8 ± 7.193.4 ± 7.4
Week 24: Resting (n= 20, 22)95.5 ± 3.494.3 ± 4.6
Week 24: End of Test (n= 20, 21)89.9 ± 7.189.3 ± 8.4
Week 24: 2 minutes after end of test (n= 20, 21)94.8 ± 4.394.8 ± 3.9
SecondaryBorg Score-Systolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods

Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Systolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Reported as:
Mean · mmHg
Borg Score-Systolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods
mmHgSTI571Placebo
Baseline: Resting (n= 26, 28)111.3 ± 14.2104.6 ± 13.2
Baseline: End of Test (n= 21, 26)119.9 ± 19.3118.3 ± 18.0
Baseline: 2 minutes after end of test (n=25, 27)120.0 ± 18.3110.4 ± 13.6
Day 32: Resting (n= 25, 27)111.4 ± 9.6106.0 ± 12.3
Day 32: End of Test (n= 22, 22)126.5 ± 17.3122.3 ± 18.6
Day 32: 2 minutes after end of test (n= 25, 26)119.6 ± 12.6113.8 ± 14.9
Week 8: Resting (n= 22, 24)108.9 ± 12.3107.3 ± 13.5
Week 8: End of Test (n= 19, 20)124.6 ± 16.1119.9 ± 17.1
Week 8: 2 minutes after end of test (n= 23, 24)115.2 ± 13.6114.5 ± 13.7
Week 12: Resting (n= 22, 23)106.5 ± 11.5107.7 ± 13.8
Week 12: End of Test (n= 17, 19)122.2 ± 17.0118.8 ± 22.9
Week 12: 2 minutes after end of test (n= 20, 22)115.9 ± 14.2115.9 ± 14.9
Week 16: Resting (n= 19, 22)106.7 ± 9.7105.7 ± 12.5
Week 16: End of Test (n= 15,18)117.2 ± 12.3119.8 ± 13.5
Week 16: 2 minutes after end of test (n= 19, 22)114.6 ± 13.8112.6 ± 15.8
Week 20: Resting (n= 19, 20)106.5 ± 7.0109.1 ± 12.1
Week 20: End of Test (n= 16,17)122.4 ± 13.3119.9 ± 19.3
Week 20: 2 minutes after end of test (n= 19, 20)115.5 ± 14.0115.1 ± 15.1
Week 24: Resting (n= 20, 21)110.6 ± 15.6108.2 ± 15.7
Week 24: End of Test (n= 16, 17)126.9 ± 23.6116.8 ± 14.9
Week 24: 2 minutes after end of test (n= 20, 19)118.2 ± 18.6111.1 ± 10.6
SecondaryBorg Score-Diastolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods

Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Diastolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Reported as:
Mean · mmHg
Borg Score-Diastolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods
mmHgSTI571Placebo
Baseline: Resting (n= 26, 28)68.2 ± 10.267.9 ± 8.9
Baseline: End of Test (n= 21, 26)75.1 ± 10.869.5 ± 11.9
Baseline: 2 minutes after end of test (n=25, 27)71.6 ± 9.867.9 ± 9.6
Day 32: Resting (n= 25, 27)69.6 ± 10.468.4 ± 8.8
Day 32: End of Test (n= 22, 22)78.2 ± 12.375.2 ± 11.2
Day 32: 2 minutes after end of test (n= 25, 26)72.5 ± 9.170.7 ± 9.4
Week 8: Resting (n= 22, 24)67.7 ± 11.868.8 ± 9.0
Week 8: End of Test (n= 19, 20)74.8 ± 10.874.0 ± 10.9
Week 8: 2 minutes after end of test (n= 23, 24)71.2 ± 10.372.2 ± 11.7
Week 12: Resting (n= 22, 23)65.5 ± 8.370.6 ± 11.6
Week 12: End of Test (n= 17, 19)75.6 ± 11.572.4 ± 14.3
Week 12: 2 minutes after end of test (n= 20, 22)73.1 ± 8.972.0 ± 13.7
Week 16: Resting (n= 19, 22)67.7 ± 9.966.7 ± 7.7
Week 16: End of Test (n= 15,18)72.7 ± 9.276.7 ± 8.6
Week 16: 2 minutes after end of test (n= 19, 22)71.4 ± 11.070.5 ± 8.0
Week 20: Resting (n= 19, 20)67.2 ± 8.069.8 ± 8.8
Week 20: End of Test (n= 16,17)72.9 ± 8.772.9 ± 8.1
Week 20: 2 minutes after end of test (n= 19, 20)71.9 ± 9.272.7 ± 9.8
Week 24: Resting (n= 20, 21)69.7 ± 10.370.7 ± 10.9
Week 24: End of Test (n= 16, 17)74.1 ± 10.772.3 ± 10.9
Week 24: 2 minutes after end of test (n= 20, 19)71.3 ± 10.172.9 ± 9.5
SecondaryBorg Score-Heart Rate (HR) During the Six Minutes Walk Test at Different Time Periods

Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Heart Rate (bpm) were recorded before the test at resting, at the end of the test and two minutes after the end of the test

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Reported as:
Mean · beats per minute (bpm)
Borg Score-Heart Rate (HR) During the Six Minutes Walk Test at Different Time Periods
beats per minute (bpm)STI571Placebo
Baseline: Resting (n= 28, 29)80.8 ± 13.087.9 ± 12.7
Baseline: End of Test (n= 28, 29)106.3 ± 23.9112.3 ± 20.4
Baseline: 2 minutes after end of test (n=26, 26)84.2 ± 16.994.1 ± 14.6
Day 32: Resting (n= 25, 28)80.7 ± 14.383.6 ± 15.7
Day 32: End of Test (n= 25, 28)108.4 ± 19.1113.1 ± 19.5
Day 32: 2 minutes after end of test (n= 25, 26)89.2 ± 17.090.6 ± 14.1
Week 8: Resting (n= 23, 25)80.3 ± 9.681.1 ± 11.2
Week 8: End of Test (n= 23, 24)109.5 ± 21.4110.3 ± 26.4
Week 8: 2 minutes after end of test (n= 23, 23)85.3 ± 15.788.9 ± 13.2
Week 12: Resting (n= 22, 25)76.5 ± 13.285.1 ± 13.2
Week 12: End of Test (n= 20, 25)105.3 ± 26.2113.0 ± 26.5
Week 12: 2 minutes after end of test (n= 19, 22)83.8 ± 17.889.4 ± 15.7
Week 16: Resting (n= 19, 24)76.5 ± 13.284.4 ± 12.9
Week 16: End of Test (n= 18, 23)102.8 ± 25.6117.9 ± 24.3
Week 16: 2 minutes after end of test (n= 19, 21)85.8 ± 21.085.5 ± 14.4
Week 20: Resting (n= 19, 22)75.3 ± 13.880.2 ± 9.6
Week 20: End of Test (n= 18,22)109.2 ± 26.8118.0 ± 24.5
Week 20: 2 minutes after end of test (n= 19, 21)83.3 ± 17.487.3 ± 11.4
Week 24: Resting (n= 20, 22)79.5 ± 13.883.6 ± 8.6
Week 24: End of Test (n= 20, 21)110.2 ± 18.1116.8 ± 21.7
Week 24: 2 minutes after end of test (n= 20, 21)87.9 ± 17.588.9 ± 11.8
SecondaryBorg Score During the Six Minutes Walk Test at Different Time Periods

Borg Score during Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Borg Score of Breathlessness was recorded using the following score of 0 to 10, how breathless do you feel? 0 is nothing at all and 10 is maximal breathlessness

Time frame:
Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Reported as:
Mean · score on a scale
Borg Score During the Six Minutes Walk Test at Different Time Periods
score on a scaleSTI571Placebo
Baseline: Resting (n= 26, 27)0.27 ± 0.830.43 ± 0.92
Baseline: End of Test (n= 27, 29)3.34 ± 2.303.02 ± 1.59
Baseline: 2 minutes after end of test (n=24, 26)0.88 ± 1.671.08 ± 1.47
Day 32: Resting (n= 25, 27)0.24 ± 0.830.48 ± 0.86
Day 32: End of Test (n= 25, 28)2.53 ± 2.023.07 ± 2.08
Day 32: 2 minutes after end of test (n= 25, 26)0.65 ± 2.061.06 ± 1.34
Week 8: Resting (n= 23, 24)0.32 ± 1.020.38 ± 0.81
Week 8: End of Test (n= 23, 25)2.46 ± 2.022.32 ± 1.64
Week 8: 2 minutes after end of test (n= 23, 24)0.32 ± 0.920.58 ± 1.04
Week 12: Resting (n= 22, 24)0.05 ± 0.210.46 ± 0.97
Week 12: End of Test (n= 22, 25)2.27 ± 1.592.92 ± 1.95
Week 12: 2 minutes after end of test (n= 22, 23)0.35 ± 0.680.65 ± 1.06
Week 16: Resting (n= 19, 23)0.13 ± 0.330.50 ± 1.23
Week 16: End of Test (n= 18, 23)2.50 ± 1.912.83 ± 1.69
Week 16: 2 minutes after end of test (n= 19, 23)0.41 ± 0.720.70 ± 1.25
Week 20: Resting (n= 19, 21)0.05 ± 0.160.67 ± 1.14
Week 20: End of Test (n= 18,22)2.31 ± 1.703.11 ± 2.17
Week 20: 2 minutes after end of test (n= 18, 20)0.31 ± 0.550.75 ± 1.15
Week 24: Resting (n= 20, 21)0.18 ± 0.490.40 ± 0.82
Week 24: End of Test (n= 20, 21)2.58 ± 1.872.93 ± 1.90
Week 24: 2 minutes after end of test (n= 20, 20)0.29 ± 0.620.67 ± 1.07
SecondaryMean Pulmonary Artery Pressure (PAP) at Baseline and Study Completion

The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including right Pulmonary Arterial Pressure (PAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · mmHg
Mean Pulmonary Artery Pressure (PAP) at Baseline and Study Completion
mmHgSTI571Placebo
Baseline breathing ambient air (n=27,28)61.7 ± 15.659.2 ± 11.6
Baseline every 2 mins breathing NO (1st) (n=20,20)61.6 ± 18.755.7 ± 12.0
Baseline every 2 mins breathing NO (2nd) (n=17,18)58.1 ± 16.753.3 ± 11.5
Baseline 5 mins after NO administration (n=20,14)60.9 ± 16.256.9 ± 10.8
Baseline 15 mins after NO administration(n=19,19)60.3 ± 16.056.5 ± 10.3
Week 24 breathing ambient air (n=20,22)52.5 ± 11.455.5 ± 11.6
Week 24 every 2 mins breathing NO (1st) (n=10,13)50.9 ± 17.555.1 ± 13.9
Week 24 every 2 mins breathing NO (2nd) (n=9,11)46.2 ± 18.153.9 ± 14.1
Week 24 5 mins after NO administration (n=10,12)47.0 ± 15.857.5 ± 12.8
Week 24 15 mins after NO administration (n=10,14)48.1 ± 13.757.2 ± 12.4
SecondaryMean Pulmonary Artery Wedge Pressure (PAWP) at Baseline and Study Completion

The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Arterial Wedge Pressure (PAWP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · mmHg
Mean Pulmonary Artery Wedge Pressure (PAWP) at Baseline and Study Completion
mmHgSTI571Placebo
Baseline breathing ambient air (n=26,28)9.0 ± 2.67.6 ± 2.3
Baseline every 2 mins breathing NO (1st) (n=20,17)9.5 ± 2.07.7 ± 2.9
Baseline every 2 mins breathing NO (2nd) (n=17,16)9.4 ± 2.27.8 ± 3.4
Baseline 5 mins after NO administration (n=19,12)9.5 ± 2.77.8 ± 2.9
Baseline 15 mins after NO administration(n=18,17)9.6 ± 2.48.1 ± 2.6
Week 24 breathing ambient air (n=19,22)8.4 ± 3.28.6 ± 2.8
Week 24 every 2 mins breathing NO (1st) (n=9,13)7.9 ± 3.110.2 ± 3.7
Week 24 every 2 mins breathing NO (2nd) (n=9,11)7.0 ± 3.410.0 ± 3.7
Week 24 5 mins after NO administration (n=10,12)7.1 ± 3.110.3 ± 3.3
Week 24 15 mins after NO administration (n=10,14)6.7 ± 2.810.4 ± 3.6
SecondaryMean Systolic Arterial Pressure (SAP) at Baseline and Study Completion

The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systolic Arterial Pressure (SAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · mmHg
Mean Systolic Arterial Pressure (SAP) at Baseline and Study Completion
mmHgSTI571Placebo
Baseline breathing ambient air (n=26,28)110.3 ± 19.5108.2 ± 15.4
Baseline every 2 mins breathing NO (1st) (n=20,19)108.3 ± 18.9106.9 ± 18.0
Baseline every 2 mins breathing NO (2nd) (n=17,17)109.9 ± 19.1105.4 ± 18.1
Baseline 5 mins after NO administration (n=21,15)106.0 ± 17.7107.1 ± 18.6
Baseline 15 mins after NO administration(n=19,19)109.5 ± 20.3106.9 ± 16.7
Week 24 breathing ambient air (n=20,22)108.0 ± 19.8106.9 ± 18.8
Week 24 every 2 mins breathing NO (1st) (n=10,13)103.9 ± 17.5102.9 ± 20.4
Week 24 every 2 mins breathing NO (2nd) (n=9,11)104.8 ± 18.3103.6 ± 19.2
Week 24 5 mins after NO administration (n=9,12)103.4 ± 18.7104.0 ± 20.0
Week 24 15 mins after NO administration (n=10,14)103.8 ± 21.4107.3 ± 18.3
SecondaryMean Heart Rate (HR) at Baseline and Study Completion

The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Heart Rate (HR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · beats per minute (bpm)
Mean Heart Rate (HR) at Baseline and Study Completion
beats per minute (bpm)STI571Placebo
Baseline breathing ambient air (n=27,28)77.3 ± 7.584.9 ± 13.0
Baseline every 2 mins breathing NO (1st) (n=20,19)75.9 ± 12.984.4 ± 15.5
Baseline every 2 mins breathing NO (2nd) (n=17,17)75.2 ± 13.683.3 ± 13.2
Baseline 5 mins after NO administration (n=19,15)73.2 ± 10.284.3 ± 13.9
Baseline 15 mins after NO administration(n=18,19)76.2 ± 9.085.1 ± 13.8
Week 24 breathing ambient air (n=20,22)76.6 ± 8.683.0 ± 12.8
Week 24 every 2 mins breathing NO (1st) (n=9,13)76.3 ± 10.182.5 ± 15.3
Week 24 every 2 mins breathing NO (2nd) (n=8,11)76.6 ± 10.382.8 ± 16.7
Week 24 5 mins after NO administration (n=9,12)75.7 ± 10.279.3 ± 10.4
Week 24 15 mins after NO administration (n=10,14)73.2 ± 8.382.9 ± 10.5
SecondaryMean Cardiac Output (CO) at Baseline and Study Completion

The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Cardiac Output (CO). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · L/min
Mean Cardiac Output (CO) at Baseline and Study Completion
L/minSTI571Placebo
Baseline breathing ambient air (n=27,28)4.20 ± 1.334.09 ± 1.44
Baseline every 2 mins breathing NO (1st) (n=19,20)4.02 ± 1.324.22 ± 1.64
Baseline every 2 mins breathing NO (2nd) (n=17,18)3.98 ± 1.164.43 ± 1.80
Baseline 5 mins after NO administration (n=19,14)4.20 ± 1.164.71 ± 1.95
Baseline 15 mins after NO administration(n=18,19)3.87 ± 1.034.47 ± 2.15
Week 24 breathing ambient air (n=20,22)4.90 ± 1.214.35 ± 1.57
Week 24 every 2 mins breathing NO (1st) (n=10,13)4.80 ± 1.264.67 ± 2.27
Week 24 every 2 mins breathing NO (2nd) (n=9,11)4.79 ± 1.314.62 ± 2.26
Week 24 5 mins after NO administration (n=10,12)4.63 ± 1.214.65 ± 1.99
Week 24 15 mins after NO administration (n=10,14)4.48 ± 1.214.46 ± 1.98
SecondaryMean Pulmonary Vascular Resistance (PVR) at Baseline and Study Completion

The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. PVR calculated according to the equation:PVR = (PAP - PCWP)/CO

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · dyn*s/cm^5
Mean Pulmonary Vascular Resistance (PVR) at Baseline and Study Completion
dyn*s/cm^5STI571Placebo
Baseline breathing ambient air (n=27,27)1124.4 ± 460.01118.3 ± 486.7
Baseline every 2 mins breathing NO (1st) (n=19,17)1180.9 ± 520.81067.9 ± 509.1
Baseline every 2 mins breathing NO (2nd) (n=17,16)1064.6 ± 458.9982.8 ± 483.9
Baseline 5 mins after NO administration (n=19,11)1131.5 ± 491.21160.4 ± 510.0
Baseline 15 mins after NO administration(n=18,16)1181.9 ± 498.71132.9 ± 461.0
Week 24 breathing ambient air (n=19,21)729.9 ± 230.11017.0 ± 369.1
Week 24 every 2 mins breathing NO (1st) (n=9,14)706.9 ± 285.51000.6 ± 501.5
Week 24 every 2 mins breathing NO (2nd) (n=9,11)687.4 ± 276.31033.6 ± 546.2
Week 24 5 mins after NO administration (n=10,12)717.2 ± 271.6987.8 ± 370.4
Week 24 15 mins after NO administration (n=10,14)776.1 ± 286.81042.5 ± 388.4
SecondaryMean Systemic Vascular Resistance (SVR) at Baseline and Study Completion

The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systemic Vascular Resistance (SVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. SVR was calculated according to the equation: SVR = (Paorta - Pright atrium)/CO

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · dyn*s/cm^5
Mean Systemic Vascular Resistance (SVR) at Baseline and Study Completion
dyn*s/cm^5STI571Placebo
Baseline breathing ambient air (n=26,26)1674.4 ± 761.21764.8 ± 481.9
Baseline every 2 mins breathing NO (1st) (n=18,15)1778.2 ± 709.51769.7 ± 457.0
Baseline every 2 mins breathing NO (2nd) (n=16,14)1807.3 ± 615.11664.7 ± 472.0
Baseline 5 mins after NO administration (n=18,11)1609.2 ± 593.41666.6 ± 488.6
Baseline 15 mins after NO administration(n=17,15)1976.3 ± 877.51748.4 ± 499.3
Week 24 breathing ambient air (n=18,21)1427.2 ± 446.81667.9 ± 357.8
Week 24 every 2 mins breathing NO (1st) (n=9,13)1344.2 ± 474.81579.3 ± 386.8
Week 24 every 2 mins breathing NO (2nd) (n=9,11)1367.9 ± 601.71592.5 ± 389.0
Week 24 5 mins after NO administration (n=9,12)1419.7 ± 566.61503.9 ± 305.3
Week 24 15 mins after NO administration (n=10,14)1431.7 ± 524.41629.3 ± 355.6
SecondaryBlood Gas Measurement - PaO2 at Baseline and Study Completion

The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaO2 levels at baseline and Study completion Week 24.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · mmHg
Blood Gas Measurement - PaO2 at Baseline and Study Completion
mmHgSTI571Placebo
Baseline n=22,2163.36 ± 14.3363.75 ± 12.02
Week 24 n=16,1772.49 ± 14.0970.13 ± 16.72
SecondaryBlood Gas Measurement - PaCO2 at Baseline and Study Completion

The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaCO2 levels at baseline and Study completion Week 24.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · mmHg
Blood Gas Measurement - PaCO2 at Baseline and Study Completion
mmHgSTI571Placebo
Baseline n=23,2132.70 ± 4.4030.02 ± 4.76
Week 24 n=16,1733.36 ± 5.1130.23 ± 3.55
SecondaryBlood Gas Measurement - PvO2 at Baseline and Study Completion

The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PvO2 levels at baseline and Study completion Week 24.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · mmHg
Blood Gas Measurement - PvO2 at Baseline and Study Completion
mmHgSTI571Placebo
Baseline n=14,1433.16 ± 4.6234.70 ± 4.75
Week 24 n=11,1135.56 ± 3.8032.65 ± 4.18
SecondaryBlood Gas Measurement - Arterial Saturation at Baseline and Study Completion

The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Arterial Saturation levels at baseline and Study completion Week 24.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · percentage of saturation
Blood Gas Measurement - Arterial Saturation at Baseline and Study Completion
percentage of saturationSTI571Placebo
Baseline n=19,1687.99 ± 9.1991.81 ± 4.05
Week 24 n=14,1592.89 ± 4.5091.78 ± 3.36
SecondaryBlood Gas Measurement - Venous Saturation at Baseline and Study Completion

The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Venous Saturation levels at baseline and Study completion Week 24.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · percentage of saturation
Blood Gas Measurement - Venous Saturation at Baseline and Study Completion
percentage of saturationSTI571Placebo
Baseline n=17,1457.96 ± 10.4860.84 ± 6.61
Week 24 n=13,1365.11 ± 6.9157.00 ± 9.18
SecondaryBlood Gas Measurement - pH at Baseline and Study Completion

The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including pH levels at baseline and Study completion Week 24. The pH scale measures how acidic or basic a substance is. It ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic.

Time frame:
Baseline, and Study completion (Week 24)
Reported as:
Mean · pH scale
Blood Gas Measurement - pH at Baseline and Study Completion
pH scaleSTI571Placebo
Baseline n=24,237.43 ± 0.047.44 ± 0.05
Week 24 n=17,177.44 ± 0.057.46 ± 0.05

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Core - STI571—12/28 (42.9%)26/28 (92.9%)
Core - Placebo—11/31 (35.5%)25/31 (80.6%)
Extension - STI571—16/22 (72.7%)21/22 (95.5%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventCore - STI571Core - PlaceboExtension - STI571
Disease progressionGeneral disorders0/280/317/22
SyncopeNervous system disorders2/281/313/22
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders2/283/311/22
Cardiac failureCardiac disorders0/280/312/22
Lung infectionInfections and infestations0/280/312/22
Cardiac arrestCardiac disorders2/282/310/22
PresyncopeNervous system disorders2/281/311/22
Right ventricular failureCardiac disorders1/282/311/22
Fluid retentionMetabolism and nutrition disorders0/282/311/22
DyspnoeaRespiratory, thoracic and mediastinal disorders0/282/311/22
Most frequent other events
Showing 10 of 80
Most frequent other events
EventCore - STI571Core - PlaceboExtension - STI571
NasopharyngitisInfections and infestations6/288/3114/22
NauseaGastrointestinal disorders14/285/318/22
Respiratory tract infectionInfections and infestations6/281/3111/22
DiarrhoeaGastrointestinal disorders6/283/319/22
Oedema peripheralGeneral disorders7/285/319/22
VertigoEar and labyrinth disorders4/284/318/22
OedemaGeneral disorders1/280/318/22
HeadacheNervous system disorders10/286/314/22
Urinary tract infectionInfections and infestations0/280/317/22
CoughRespiratory, thoracic and mediastinal disorders2/286/317/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)STI571PlaceboTotal
Mean44.4 ± 15.344.2 ± 15.744.3 ± 15.4
Sex: Female, Male
Sex: Female, Male(Participants)STI571PlaceboTotal
Female182240
Male10919
08

Study locations

13 sites
  • Novartis Investigative Site
    Los Angeles, California 90073, United States
  • Novartis investigative site
    Newark, New Jersey 07112, United States
  • Novartis Investigative Site
    New York, New York 10032, United States
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative site
    Graz, Austria
  • Novartis Investigative Site
    Giessen, 35385, Germany
  • Novartis Investigative site
    Giessen, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative site
    Hannover, Germany
  • Novartis Investigative Site
    Cambridge, Cambridgeshire CB23 3RE, United Kingdom
  • Novartis Investigative Site
    Glasgow, G11 6NT, United Kingdom
  • Novartis Investigative site
    Glasgow, United Kingdom
  • Novartis Investigative site
    Papworth, United Kingdom
09

References and documents

Publications

  • Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7. doi: 10.1164/rccm.201001-0123OC. Epub 2010 Jun 25. PubMed 20581169 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2007
First posted
May 23, 2007
Start
Apr 2006
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Mar 23, 2015
Last update
Mar 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00477269
Responsible party
Sponsor
First posted
May 23, 2007
Start date
Apr 2006
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Mar 23, 2015
Last update
Mar 23, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
Novartis
principal investigator · Investigative site

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion